

Bharat Pet Limited

CIN : U25209DL1998PLC091888
 Unaudited Proforma Consolidated Statement of Assets and Liabilities
 (All amounts in INR million, unless otherwise stated)

Particulars	Note No.	As at September 30, 2025					As at March 31, 2025						
		A	B	C	D	E=C+D	F=A+B+E	A	B	C	D	E=C+D	F=A+B+E
		Restated Statement of Assets and Liabilities of Bharat Pet Limited as at September 30, 2025	Special Purpose Consolidated Balance Sheet of BPL Lifescience Private Limited as at September 30, 2025	Intra Group Eliminations	Acquisition Adjustments	Total Pro-Forma Adjustments	Proforma Consolidated Balance Sheet of Bharat Pet Limited	Restated Statement of Assets and Liabilities of Bharat Pet Limited as at March 31, 2025	Special Purpose consolidated Balance Sheet of Lifescience Private Limited as at March 31, 2025	Intra Group Eliminations	Acquisition Adjustments	Total Pro-Forma Adjustments	Proforma Consolidated Balance Sheet of Bharat Pet Limited
ASSETS													
Non-current assets													
Property, plant and equipment	5	828.46	564.97	-	-	-	1,393.43	669.53	567.61	-	-	-	1,237.14
Right of Use	5A	99.78	11.86	-	-	-	111.64	49.85	12.01	-	-	-	61.86
Capital work in Progress	6	90.66	3.15	-	-	-	93.81	49.15	3.15	-	-	-	52.30
Financial assets		-	-	-	-	-	-	-	-	-	-	-	-
(i) Investments		-	-	-	-	-	-	-	-	-	-	-	-
(ii) Loans		-	-	-	-	-	-	-	-	-	-	-	-
(iii) Other financial assets	7	20.99	28.24	-	-	-	49.23	22.29	26.10	-	-	-	48.39
Deferred Tax Asset (Net)	8	25.50	-	-	-	-	25.50	24.24	-	-	-	-	24.24
Other non-current assets	9	8.46	-	-	-	-	8.46	4.54	-	-	-	-	4.54
		1,073.85	608.22	-	-	-	1,682.08	819.60	608.87	-	-	-	1,428.47
Current assets													
Inventories	10	309.64	77.20	-	-	-	386.84	485.65	137.11	-	-	-	622.76
Financial assets		-	-	-	-	-	-	1.46	-	-	-	-	1.46
(i) Investments	11	-	-	-	-	-	-	-	-	-	-	-	-
(ii) Loans	12	7.19	1.03	-	-	-	8.22	2.56	0.03	-	-	-	2.59
(iii) Trade receivables	13	1,724.27	364.54	(0.14)	-	(0.14)	2,088.67	1,036.53	175.39	-	-	-	1,211.92
(iv) Cash and cash equivalents	14	2.95	1.57	-	-	-	4.52	1.81	1.15	-	-	-	2.96
(v) Bank balances other than (iv) above	15	0.06	17.70	-	-	-	17.76	0.06	26.94	-	-	-	27.00
(vi) Other financial assets	16	54.06	90.45	-	-	-	144.51	89.83	83.96	-	-	-	83.96
Other current assets	17	258.57	258.57	-	-	-	517.14	194.95	194.95	-	-	-	389.90
		2,098.17	811.05	(0.14)	-	(0.14)	2,909.08	1,617.90	619.53	-	-	-	2,237.43
Total Assets		3,172.02	1,419.27	(0.14)	-	(0.14)	4,591.15	2,437.50	1,228.41	-	-	-	3,665.91
EQUITY AND LIABILITIES													
EQUITY													
Equity share capital	18	947.75	2.00	-	(2.00)	(2.00)	947.75	947.75	2.00	-	(2.00)	(2.00)	947.75
Other equity	19	452.66	267.97	-	(292.03)	(292.03)	428.60	118.89	119.90	-	(269.82)	(269.82)	(31.03)
Equity attributable to equity holders of the parent		1,400.41	269.97	-	(294.03)	(294.03)	1,376.35	1,066.64	121.90	-	(271.82)	(271.82)	916.72
Non-Controlling Interest	20	-	1.75	-	40.50	40.50	42.25	-	1.75	-	18.29	18.29	20.04
Total Equity		1,400.41	271.72	-	(253.54)	(253.54)	1,418.59	1,066.64	123.65	-	(253.54)	(253.54)	936.75




Handwritten signatures and initials in blue ink, including a large signature and the letters 'Pq'.

Bharat Pet Limited

CIN : U25209DL1998PLC091888
 Unaudited Proforma Statement of Profit and Loss
 (All amounts in INR million, unless otherwise stated)

Particulars	Note No.	For the period ended September 30, 2025						For the year ended March 31, 2025						
		Restated Statement of Profit and Loss of Bharat Pet Limited for the period ended September 30, 2025		Special Purpose consolidated Statement of Profit & Loss of BPL Lifescience Private Limited for the period ended September 30, 2025		Proforma Consolidated Statement of Profit and Loss of Bharat Pet Limited		Restated Statement of Profit and Loss of Bharat Pet Limited for the year ended March 31, 2025		Special Purpose consolidated Statement of Profit and Loss of BPL Lifescience Private Limited for the year ended March 31, 2025		Proforma Consolidated Statement of Profit and Loss of Bharat Pet Limited		
		A	B	C	D	E=C+D	F=A+B+E	A	B	C	D	E=C+D	F=A+B+E	
INCOME														
Revenue from operations	32	2,268.13	498.59	(17.73)	-	(17.73)	2,748.99	3,328.62	817.91	(28.32)	-	(28.32)	4,118.21	
Other income	33	2.96	94.54	-	-	-	97.50	12.42	147.28	-	-	-	159.70	
Total income		2,271.09	593.13	(17.73)	-	(17.73)	2,846.49	3,341.04	965.19	(28.32)	-	(28.32)	4,277.91	
EXPENSES														
Cost of materials consumed	34	1,224.44	255.71	(17.56)	-	(17.56)	1,462.59	1,967.95	513.51	(27.83)	-	(27.83)	2,453.63	
Changes in inventories of finished goods, stock-in-trade and work-in-progress	35	27.16	19.64	-	-	-	46.80	(31.59)	(48.37)	-	-	-	(79.96)	
Employee benefits expense	36	85.81	9.44	(0.13)	-	(0.13)	95.12	157.98	16.21	(0.14)	-	(0.14)	174.05	
Finance costs	37	41.63	35.96	-	-	-	77.59	52.18	82.03	-	-	-	134.21	
Depreciation and amortisation expense	38	78.34	42.04	-	-	-	120.38	104.99	118.78	-	-	-	223.77	
Other expenses	39	371.93	58.93	(0.03)	-	(0.03)	430.83	591.18	100.35	(0.35)	-	(0.35)	691.18	
Total expenses		1,829.31	421.72	(17.73)	-	(17.73)	2,233.31	2,842.69	782.51	(28.32)	-	(28.32)	3,596.88	
Profit/ (loss) before exceptions items and tax		441.78	171.41	-	-	-	613.19	498.35	182.68	-	-	0.00	681.04	
Exceptional Items Profit/(Loss)														
Profit/ (loss) before tax		441.78	171.41	-	-	-	613.19	498.35	182.68	-	-	0.00	681.04	
Tax expense	40													
Current tax		110.17	27.05	-	-	-	137.22	136.30	23.97	-	-	-	160.27	
Deferred tax		(1.49)	(3.72)	-	-	-	(5.21)	(5.63)	16.52	-	-	-	10.89	
Total Tax expense		108.68	23.33	-	-	-	132.01	130.67	40.49	-	-	-	171.16	
Profit for the year		333.10	148.08	-	-	-	481.18	367.68	142.19	-	-	-	509.88	



Bharat Pet Limited

CIN : U25209DL1998PLC091888

Unaudited Proforma Consolidated Statement of Cash Flow

(All amounts in INR million, unless otherwise stated)

S.No.	Particulars	For the period ended September 30, 2025	For the year ended March 31, 2025
A	Cash Inflow / (Outflow) from Operating Activities		
	Net Restated Profit Before Tax	613.19	681.04
	Less: Profit under common control transaction	-	-
	Adjustment for:		
	Depreciation and amortisation expense	120.38	223.77
	Interest income	(1.05)	(4.65)
	(Profit)/Loss on sale of PPE	(1.77)	0.16
	Profit on sale of Investments	(0.32)	-
	Fair valuation gain on investments carried at FVTPL (net)	-	(5.80)
	Capital work in progress written off	-	1.18
	Finance cost	77.59	134.21
	Non Controlling Interest	-	0.44
	Foreign exchange fluctuation	1.45	0.24
	Operating cash flow before working capital changes	809.47	1,030.59
	Adjustment for working capital changes:		
	(Increase)/Decrease in trade receivables	(878.34)	(295.71)
	(Increase)/Decrease in inventories	235.93	(288.09)
	(Increase)/Decrease in other financial assets	4.06	(78.74)
	(Increase)/Decrease in other assets	(31.21)	(207.32)
	Increase / (Decrease) in trade payables	183.74	51.72
	Increase / (Decrease) in other financial liabilities	21.59	(64.39)
	Increase / (Decrease) in other liabilities	8.40	117.40
	Cash generated from/(used in) operations	353.64	265.46
	Income tax paid (net)	(128.71)	(164.26)
	Net Cash Inflow / (Outflow) from Operating Activities (A)	224.93	101.20
B	Cash Inflow/(Outflow) from Investing Activities		
	Sale/(Purchase) of property, plant and equipment including CWIP (net)	(301.07)	(352.47)
	Payment of purchase consideration for acquisition of business	(532.92)	(272.08)
	Loan (given)/recovered (net)	(4.63)	10.90
	Sale/(Purchase) of investments	1.78	74.71
	Interest Received	0.59	4.34
	Net Cash Inflow / (Outflow) from Investing Activities (B)	(836.25)	(534.60)
C	Cash Inflow/(Outflow) from Financing Activities		
	Proceeds/(repayment) of borrowings (net)	702.99	561.74
	Capital infusion by Non Controlling Interest	-	1.75
	Interest Paid	(75.29)	(130.98)
	Payment of Lease Liability	(14.82)	(7.64)
	Cash Inflow / (Outflow) from Financing Activities (C)	612.88	424.87
	Net Changes in Cash and Cash Equivalents (A+B+C)	1.55	(8.53)
	Cash and Cash Equivalents (Opening Balance)	2.96	11.50
	Cash and Cash Equivalents (Closing Balance)	4.52	2.96

The above cash flow statement has been prepared under the indirect method set out in Ind AS 7 - Statement of Cash Flows

As per our report of even date
For Prateek Gupta & Company
Chartered Accountants
Firm Registration No.: 016512C

Prateek Gupta
Partner
Membership No..416552



Place: Delhi

Date: March 21, 2026

UDIN:26416552YQZAQH3496

On behalf of the Board of Directors of Bharat Pet Limited

Ankur Gupta
Managing Director
DIN: 02740748

Deepak Gupta
Chairman, Whole Time
Director and Chief Financial
Officer
DIN: 00703704

Rahul Gupta
Whole Time Director
DIN: 07185069

CS Surjit Singh
Company Secretary and
Compliance Officer

Membership Number-F7173

Bharat Pet Limited

CIN : U25209DL1998PLC091888

Notes to Unaudited Proforma Consolidated Financial Statements

(All amounts in INR million, unless otherwise stated)

1) Corporate Information and Background

The Company "Bharat Pet Limited" is engaged in business of manufacturing of polyethylene terephthalate ("PET") bottles and jars, multi-layer co-extrusion ("Co-Ex") bottles, Preforms, Cap & closures and tin containers. The Company operates from 3 manufacturing plant based out of Sonipat (Haryana), Ankleshwar(Gujarat) and Delhi.

On January 31, 2026, the Company has acquired 85% of equity shares of BPL Lifesciences Private Limited by virtue which it became its subsidiary and the BPL Lifescience has manufacturing plant based out of Samba (Jammu & Kashmir).

The registered and corporate office of the Company is at Plot I-12, 2nd Floor, Rohtak Road Nangloi, DSIDC, Industrial Complex, New Delhi- 110041. Corporate Identification Number of the Company is U25209DL1998PLC091888.

The Company "BPL Lifescience Private limited" is engaged in business of manufacturing of polyethylene terephthalate ("PET") bottles and jars, multi-layer co-extrusion ("Co-Ex") bottles, Preforms and caps & closures. The Company operates 1 manufacturing plant based out of Samba (Jammu & Kashmir).

The registered and corporate office of the Company is at Plot No. I-12, First Floor, DSIDC Industrial Complex, Rohtak Road, Nangloi, West Delhi, New Delhi, Delhi, India, 110041. Corporate Identification Number of the Company is U24299DL2019PTC357272.

2) Basis of Preparation

The Unaudited Proforma Consolidated Financial Information as at and for the period and year ended September 30, 2025 and March 31, 2025 have been prepared by the management of Company in accordance with the requirements of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended to date (the "SEBI Regulations") issued by the Securities and Exchange Board of India (the "SEBI"), in respect of above acquisition for which financial information is disclosed in the Draft Red Herring Prospectus ("DRHP"), considering that the acquisition is material for the purpose of the business.

The Unaudited Proforma Consolidated Financial Information have been prepared specifically for inclusion in the DRHP to be filed by the Company with SEBI in connection with proposed Initial Public Offering ("IPO")

The Unaudited Proforma Consolidated Financial Information has been prepared by the Company to illustrate the impact of acquisition transaction undertaken as if the acquisition had taken place:

1. on September 30, 2025 and March 31, 2025 respectively for the purpose of unaudited proforma consolidated balance sheet as at September 30, 2025 and March 31, 2025 and
2. on April 01, 2025, and April 01, 2024 respectively for the purpose of unaudited proforma consolidated statement of profit and loss for the period and year ended September 30, 2025, and March 31, 2025.

The Unaudited Proforma Consolidated Financial Information are derived from:

- i) restated financial information of the company for September 30, 2025 and March 31, 2025,
- ii) Audited Consolidated Special Purpose Ind AS Financial Statements of BPL Lifescience Private Limited for the period and year ended September 30, 2025 and March 31, 2025 respectively.

Adjusted for intercompany eliminations, uniformity of accounting policies and acquisition adjustments for the Acquired company mentioned above, as if the transaction related to such acquisition to obtain control over the Acquired company had occurred on September 30, 2025 and March 31, 2025 for the purpose of unaudited proforma balance sheet.

Further, the unaudited proforma statement of profit and loss for the period and year ended September 30, 2025 and March 31, 2025 has been illustrated to reflect the Acquired company as if the transaction related to acquisition to obtain control over Acquired company occurred on and from April 01, 2025 and April 01, 2024 respectively. The description of adjustments made to the Unaudited Proforma Financial Information are included in the note 3 below.



The Unaudited Proforma Consolidated Financial Information are presented in Indian Rupees which is also the Holding Company's functional currency. All values are rounded to the nearest million except when otherwise stated.

The Unaudited Proforma Consolidated Financial Information were approved by the Board of Directors of the Company on March 21, 2026.

Because of the nature, the Unaudited Proforma Consolidated Financial Information addresses a hypothetical situation and therefore, does not represent the Company's factual financial position or results. Accordingly, the Unaudited Proforma Consolidated Financial Information does not necessarily reflect what the Company's financial condition or results of operations would have been had the acquisition occurred on the dates indicated and is also not intended to be indicative of expected financial position or results of operations in future periods. The actual consolidated balance sheet, consolidated statement of profit and loss may differ significantly from the proforma amounts reflected herein due to variety of factors.

The assumptions and estimates underlying the adjustments to the Unaudited Proforma Consolidated Financial Information are described hereinafter which should be read together with the unaudited proforma consolidated statement of assets and liabilities, unaudited proforma consolidated statement of profit and loss.

The Unaudited Proforma Financial Information should be read together with the Group's restated consolidated financial information and the Special Purpose Ind AS Consolidated Financial Statements of Acquired company.

The proforma adjustments are based upon available information and assumptions that the management of the Company believes to be reasonable. Accordingly, the degree of reliance placed by anyone on such Unaudited Proforma Consolidated Financial Information should be limited.



Bharat Pet Limited

CIN : U25209DL1998PLC091888

Notes to the proforma consolidated financial information*(All amounts in INR million, unless otherwise stated)***Note 3: Pro forma adjustments****(A) Acquisition adjustments**

The acquisition of BPL Life Sciences Private Limited has been accounted as business combination of entities under common control, using pooling of interests method under Ind AS 103, Business Combinations. Accordingly:

The assets and liabilities of BPL Lifescience Private Limited are reflected at their carrying amounts in the columns identified as "Acquisition".

No adjustments are made to reflect fair values of net assets acquired. However, Fair value of net assets of BPL Lifescience Private Limited A Liability has been recognised in respect of the equity share purchased by the company of BPL Lifescience Private Limited made subsequent to September 30, 2025 of Rs 253.54 million and the same has been disclosed under other current financial liabilities.

The reserves of BPL Lifescience Private Limited, including retained earnings (presented as other equity), have become the reserves of the Company.

The difference between the amount of consideration and the amount of share capital of BPL Lifescience Private Limited is transferred to common control reserve within other equity.

The purchase price as on the date of acquisition has been provisionally allocated to the acquired assets and liabilities as follows:

Particulars	As at September 30, 2025	As at March 31, 2025
Purchase consideration (including Fair value of existing investment as on the date of acquisition)(a)	253.54	253.54
Fair value of net assets acquired*(b)	269.98	121.90
Deferred tax liabilities on fair value adjustments(c)	-	-
Share of Non Controlling Interest(d)	40.50	18.29
Common Control Reserve(a-b-c+d)	(24.06)	(149.93)

Note:

The Common control Reserve and other acquisition related adjustments computed in case of acquisition of the above entity and business are based on NIL purchase price allocation ("PPA"). The final allocation could differ materially from the provisional allocation used in proforma adjustments.

(B) Non-controlling interests

The Company acquired 85.00% of equity share capital of BPL Lifescience Private Limited. Accordingly, the remaining 15.00% equity interest is held by non-controlling interests.

The following table presents adjustments recorded to recognise non-controlling interests.

Description	As at September 30, 2025	As at March 31, 2025
Adjustment in pro forma balance-sheet		
Total equity of BPL Lifescience Private Limited	269.97	121.89
Non-controlling interests at 15.00%	40.50	18.28
Adjustment in pro forma statement of profit and loss		
Profit for the period/year	148.08	142.19
Share of non-controlling interests	22.21	21.33
Other comprehensive income for the period/year	-	-
Share of non-controlling interests	-	-



(C) **Earnings per share**

The pro forma basic and diluted earning per share for the period and year ended September 30, 2025 and March 31, 2025 are calculated as

Description	For the period ended September 30, 2025	For the year ended March 31, 2025
Pro forma profit after tax attributable to owners of the parent - (A)		
Weighted average number of equity shares outstanding (in nos.) used for calculation of basic EPS - as per restated financial information - (B)	458.97	488.91
Basic earnings per share (Rs.) - (A/B)	9,47,75,010	9,47,75,010
Weighted average number of equity shares outstanding (in nos.) used for calculation of diluted EPS - as per restated financial information - (C)	4.84	5.16
Diluted earnings per share (Rs.) - (A/C)	9,47,75,010	9,47,75,010
Nominal value of equity shares	4.84	5.16
	10	10

Note 4: Inter-company eliminations:

These adjustments reflect eliminations on account of intra-group transactions between Bharat Pet Limited and acquired entities BPL Lifescience Private Limited for the periods presented. Adjustments on account of intragroup transactions and balances between the Company and BPL Lifescience Private Limited are as follows:

Particulars	As at September 30, 2025	As at March 31, 2025
Proforma Consolidated Statement of Profit and Loss		
Decrease in Revenue from operations	(17.73)	(28.32)
Decrease in Cost of materials consumed	(17.56)	(27.83)
Decrease in Employee Benefit Expenses	(0.13)	(0.14)
Decrease in Other expenses	(0.03)	(0.35)



Note-5: Property, Plant and Equipments

Description of Assets	Building		Land		Plant & Machinery		Moulds and Dies		Office Equipment		Laboratory equipment		Computer & Data processing unit		Furniture & Fixture		Motor Vehicles		Intra Group Eliminations/Adjustments	Acquisitions	Total		
	Restated Statement of Assets and Liabilities of	Special Purpose Consolidated	Restated Statement of Assets and Liabilities of	Special Purpose Consolidated	Restated Statement of Assets and Liabilities of	Special Purpose Consolidated	Restated Statement of Assets and Liabilities of	Special Purpose Consolidated	Restated Statement of Assets and Liabilities of	Special Purpose Consolidated	Restated Statement of Assets and Liabilities of	Special Purpose Consolidated	Restated Statement of Assets and Liabilities of	Special Purpose Consolidated	Restated Statement of Assets and Liabilities of	Special Purpose Consolidated	Restated Statement of Assets and Liabilities of	Special Purpose Consolidated			Bharat Petroleum Limited (A)	Private Limited (B)	Total (A+B)
I. Gross Carrying Amount																							
Balance as at March 31, 2024	121.60	85.19	46.13	323.65	163.32	7.18	32.53	8.23	0.01	0.15	0.48	0.24	1.55	0.94	4.98	0.24	7.46	0.34	-	-	702.74	652.34	1,355.08
Addition on account of common control transaction	-	1.80	-	29.89	15.07	7.48	-	0.01	-	0.15	-	-	0.15	-	0.12	-	7.46	-	-	-	-	-	-
Deletion on account of common control transaction	7.37	12.87	27.79	115.64	54.02	6.84	4.23	-	-	0.48	0.08	-	-	-	1.21	0.63	-	-	-	-	54.52	66.24	279.59
Adjustments	-	-	-	0.12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deletion on account of common control transaction	-	-	-	(5.69)	(5.37)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deletion on account of common control transaction	-	-	-	(3.59)	(3.15)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Balance as at March 31, 2025	128.97	98.05	46.13	510.04	342.33	21.50	36.77	8.24	0.01	2.18	0.32	2.18	1.55	0.94	6.31	0.32	7.46	0.34	-	-	946.18	715.43	1,661.61
Addition on account of common control transaction	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deletion on account of common control transaction	0.93	5.25	2.37	156.92	20.70	13.56	0.19	-	-	0.21	0.02	-	0.21	-	0.58	0.02	27.05	-	-	-	243.14	39.40	282.54
Deletion on account of common control transaction	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deletion on account of common control transaction	-	-	-	(21.65)	(3.89)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Adjustments	-	-	-	(0.34)	(0.24)	(0.03)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Balance as at September 30, 2025	129.90	103.30	44.33	644.96	363.04	35.02	36.96	8.24	0.01	2.39	0.34	2.39	1.66	0.94	6.89	0.34	33.05	0.09	-	-	1,161.69	754.58	1,916.27
II. Accumulated Depreciation																							
Balance as at March 31, 2024	19.34	1.98	-	112.24	14.39	3.39	1.95	3.01	0.01	1.03	0.03	1.03	0.03	0.02	1.20	0.03	3.87	0.03	-	-	187.81	29.34	217.15
Depreciation for the year	7.17	7.77	-	30.31	57.75	2.91	9.09	-	-	0.23	0.17	-	0.23	-	0.60	0.17	0.77	0.09	-	-	67.16	118.62	185.78
Depreciation on account of common control transaction	1.59	-	-	20.27	6.90	2.64	-	0.04	-	0.17	-	-	0.17	-	0.25	-	-	-	-	-	-	-	-
Depreciation on disposal of asset	-	-	-	(2.74)	(0.15)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation on disposal of asset under common control transaction	-	-	-	(4.48)	(0.89)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other adjustments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Balance as at March 31, 2025	28.10	9.75	-	155.60	71.90	8.94	11.04	3.05	0.01	1.45	0.19	1.45	1.45	0.02	2.05	0.19	4.64	0.12	-	-	276.65	147.81	424.46
Depreciation for the year	4.86	4.69	-	38.16	22.36	4.02	2.27	-	-	0.21	0.05	-	0.21	-	0.42	0.05	1.45	0.02	-	-	66.64	41.89	108.53
Depreciation on account of common control transaction	-	-	-	(7.64)	(1.69)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation on disposal of asset	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation on disposal of asset under common control transaction	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other adjustments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Balance as at September 30, 2025	32.96	13.74	-	186.12	94.35	12.96	13.31	3.05	0.01	1.66	0.24	1.66	0.53	0.02	2.47	0.24	5.36	0.03	-	-	333.23	189.60	522.84
III. Net Carrying amount (I-II)																							
As at September 30, 2025	96.94	89.56	44.33	458.85	268.68	22.06	23.65	5.19	0.01	0.73	0.10	0.73	1.16	0.06	4.42	0.10	27.69	0.06	-	-	828.46	564.97	1,393.43
As at March 31, 2025	100.87	88.30	46.13	354.44	270.34	12.56	25.73	5.19	0.01	0.73	0.13	0.73	1.21	0.06	4.26	0.13	2.92	0.21	-	-	669.53	567.61	1,237.14



Bharat Pet Limited

CIN : U25209DL1998PLC091888

Notes to Unaudited Proforma Consolidated Financial Statements

(All amounts in INR million, unless otherwise stated)

Note 5A: Right of use assets (ROU)

Description of Assets Particulars	ROU		Total
	Restated Statement of Assets and Liabilities of Bharat Pet Limited as at September 30, 2025	Special Purpose Consolidated Balance Sheet of BPL Lifescience Private Limited as at September 30, 2025	
I. Gross Carrying Amount			
Balance as at March 31, 2024	-	12.66	12.66
Addition	55.82	0.04	55.86
Deletion	-	-	-
Balance as at March 31, 2025	55.82	12.70	68.52
Addition	61.63	-	61.63
Deletion	-	-	-
Balance as at September 30, 2025	117.45	12.70	130.15
II. Amortisation			
Balance as at March 31, 2024	-	0.38	0.38
Amortisation for the year	5.97	0.31	6.28
Amortisation on disposal of asset	-	-	-
Balance as at March 31, 2025	5.97	0.69	6.66
Amortisation for the year	11.70	0.15	11.85
Amortisation on disposal of asset	-	-	-
Balance as at September 30, 2025	17.67	0.84	18.51
III. Net Carrying amount (I-II)			
As at September 30, 2025	99.78	11.86	111.64
As at March 31, 2025	49.85	12.01	61.86



Bharat Pet Limited

CIN : U25209DL1998PLC091888

Notes to Proforma Consolidated Statement of Assets and Liabilities
(All amounts in INR million, unless otherwise stated)

Particulars	As at September 30, 2025				As at March 31, 2025					
	Restated Statement of Assets and Liabilities of Bharat Pet Limited as at September 30, 2025	Special Purpose Consolidated Balance Sheet of Lifescience Private Limited as at September 30, 2025	Intra Group Eliminations	Acquisition Adjustments	Proforma Consolidated Balance Sheet of Bharat Pet Limited	Restated Statement of Assets and Liabilities of Bharat Pet Limited as at March 31, 2025	Special Purpose Consolidated Balance Sheet of Private Limited as at March 31, 2025	Intra Group Eliminations	Acquisition Adjustments	Proforma Consolidated Balance Sheet of Bharat Pet Limited
Note 6: Capital Work in Progress										
Opening Balance	49.15	3.15	-	-	52.30	0.19	-	-	20.41	20.60
Additions	48.03	-	-	-	48.03	3.15	-	-	49.83	52.98
Amount capitalised to Property, Plant and Equipment	(6.52)	-	-	-	(6.52)	(0.19)	-	-	(21.09)	(21.28)
Total	90.66	3.15	-	-	93.81	3.15	-	-	49.15	52.30
Note 7: Other Financial Assets(Non Current)										
Considered good (unless otherwise stated)										
Security deposit	20.99	0.01	-	-	21.00	0.01	-	-	22.29	22.30
Government Grant, Capital Interest Subvention recoverable	-	19.61	-	-	19.61	26.09	-	-	-	26.09
Bank Deposits with original maturity of more than 12 months	-	8.62	-	-	8.62	-	-	-	-	-
Total	20.99	28.24	-	-	49.23	26.10	-	-	22.29	48.39
Note 8 : Deferred Tax Liabilities/(Assets) (Net)										
Deferred tax assets/ liabilities are attributable to the following items:										
Deferred Tax Liabilities on:										
-Depreciation and Amortization expenses	-	7.93	-	-	7.93	-	-	-	-	11.65
-Net lease liability	0.20	-	-	-	0.20	-	-	-	0.29	0.29
-Disallowance u/s 43B	(0.13)	-	-	-	(0.13)	-	-	-	0.13	0.13
-Disallowance u/s 35	(0.41)	-	-	-	(0.41)	-	-	-	1.63	1.63
Deferred Tax Asset on:										
-Acquired under common control transaction (refer note 47)	-	-	-	-	-	-	-	-	(22.09)	-
-Property, Plant and Equipment	(20.40)	-	-	-	(20.40)	-	-	-	(0.79)	(22.09)
-Gratuity Provision	(3.64)	-	-	-	(3.64)	-	-	-	(3.41)	(0.79)
-Provision for credit impaired	(1.12)	-	-	-	(1.12)	-	-	-	(3.41)	(3.41)
Net Deferred tax liabilities/(Assets)	(25.50)	7.93	-	-	(17.57)	11.65	-	-	(24.24)	(12.59)
Note 9: Other Non-Current Assets										
Capital Advance	8.46	-	-	-	8.46	-	-	-	4.54	4.54
Total	8.46	-	-	-	8.46	-	-	-	4.54	4.54



Note 17: Other Current assets									
Advance to supplier	24.18	11.73	-	35.91	64.68	12.82	-	77.50	
GST Refund Recoverable	-	231.63	-	231.63	-	141.89	-	141.89	
Other receivables	15.66	1.86	-	17.52	1.52	0.22	-	1.74	
Balance with government authorities	3.13	12.59	-	15.72	19.25	37.96	-	57.21	
Deposit of Earnest money	-	-	-	-	0.58	-	-	0.58	
Prepaid expenses	11.09	0.76	-	11.85	3.80	2.06	-	5.86	
Total	54.06	258.57	-	312.63	89.83	194.95	-	284.78	
Note 18: Equity Share Capital									
Authorised Share Capital									
Number of shares	9,50,00,000.00	20,00,000.00	-	9,50,00,000.00	9,50,00,000.00	20,00,000.00	-	9,50,00,000.00	
Face Value (Rs.)	10	10	-	10.00	10.00	10.00	-	10.00	
Amount	950.00	20.00	-	950.00	950.00	20.00	-	950.00	
Total	950.00	20.00	-	950.00	950.00	20.00	-	950.00	
Issued, subscribed and fully paid up shares									
Number of shares	9,47,75,010.00	2,00,000.00	-	9,47,75,010.00	9,47,75,010.00	2,00,000.00	-	9,47,75,010.00	
Face Value (Rs.)	10.00	10.00	-	10.00	10.00	10.00	-	10.00	
Amount	947.75	2.00	-	947.75	947.75	2.00	-	947.75	
Total	947.75	2.00	-	947.75	947.75	2.00	-	947.75	
Note 19: Other Equity									
Security Premium Reserve									
Opening Balance	-	-	-	-	29.13	-	-	29.13	
Utilisation on account of bonus issue	-	-	-	-	(29.13)	-	-	(29.13)	
Closing Balance	-	-	-	-	-	-	-	-	
Capital Redemption Reserve									
Opening Balance	-	-	-	-	1.81	-	-	1.81	
Utilisation on account of bonus issue	-	-	-	-	(1.81)	-	-	(1.81)	
Closing Balance	-	-	-	-	-	-	-	-	
Retained Earnings									
Opening Balance	219.96	119.89	-	219.96	895.68	(22.30)	-	895.68	
Restated Profit for the year	333.10	148.08	-	333.10	367.68	142.19	-	367.68	
Utilisation on account of bonus issue	-	-	(119.89)	-	(894.77)	-	(142.19)	(894.77)	
Transfer to common control reserve	-	-	(148.08)	-	(148.90)	-	-	(148.90)	
Other comprehensive income (net of tax)	0.67	-	-	0.67	0.27	-	-	0.27	
Closing Balance	553.73	267.97	(267.97)	553.73	219.96	119.89	(119.89)	219.96	
Capital Reserve									
Opening Reserve	-	0.01	-	0.01	-	0.01	-	0.01	
Closing Balance	-	0.01	-	0.01	-	0.01	-	0.01	
Common Control Reserve									
Opening Balance	(101.07)	-	(149.93)	(251.00)	(249.97)	-	-	(520.77)	
Transfer to common control reserve	-	-	125.87	125.87	148.90	-	-	269.76	
Closing Balance	(101.07)	-	(24.06)	(125.13)	(101.07)	-	(149.93)	(251.01)	
Total Other Equity	452.66	267.97	(292.03)	428.61	118.89	119.90	(269.82)	(31.04)	



Note 20: Non-Controlling Interest										
Opening Balance	-	1.75	-	-	1.75	-	-	-	0.04	0.04
Proportionate profit share	-	-	-	-	-	-	-	-	(0.04)	-
Addition	-	-	40.50	-	40.50	-	-	-	1.75	18.29
	-	1.75	-	40.50	42.25	-	-	-	1.75	18.29
										20.04
Note 21 : Borrowings (Non Current)										
Secured										
Term Loans:										
- From Banks	360.88	371.94	-	-	732.82	66.68	404.47	-	-	471.15
- From Financial Institutions	-	-	-	-	-	-	-	-	-	-
Vehicle Loans:										
- From Banks	17.33	-	-	-	17.33	-	-	-	-	-
Unsecured										
Loans from Related parties	81.69	414.88	-	-	496.57	197.82	364.08	-	-	561.90
Total Secured and unsecured borrowings	459.90	786.82	-	-	1,246.72	264.50	768.55	-	-	1,033.05
Less Current Maturity of long term borrowings	68.56	64.83	-	-	133.39	26.82	66.00	-	-	92.82
Total	391.34	721.99	-	-	1,113.33	237.68	702.55	-	-	940.23
Note 22: Lease Liabilities (Non Current)										
Lease Liabilities	75.76	0.91	-	-	76.67	39.90	0.81	-	-	40.71
Total	75.76	0.91	-	-	76.67	39.90	0.81	-	-	40.71
Note No : 23 Provisions (Non- Current)										
Gratuity	12.74	-	-	-	12.74	11.90	-	-	-	11.90
Compensated Absences	-	-	-	-	-	0.05	-	-	-	0.05
Total	12.74	-	-	-	12.74	11.95	-	-	-	11.95
Note 24: Other Non Current Liabilities										
Deferred Revenue - Capital Interest Subvention	-	51.77	-	-	51.77	-	53.59	-	-	53.59
Total	-	51.77	-	-	51.77	-	53.59	-	-	53.59
Note 25: Borrowings (Current)										
Secured										
a. Loans repayable on demand										
- Cash Credit with bank	602.85	223.99	-	-	826.84	349.78	187.74	-	-	537.52
- Working Capital Loan	200.00	-	-	-	200.00	-	-	-	-	-
b. Current maturities of long term borrowings										
	68.56	64.83	-	-	133.39	26.82	66.00	-	-	92.82
Total	871.41	288.82	-	-	1,160.23	376.60	253.74	-	-	630.34



Note 26 : Trade Payables									
Trade Payables									
Total outstanding of Micro Enterprises and Small Enterprises	62.74	8.07	(0.14)	-	70.67	30.45	6.84	-	37.29
Total outstanding of creditors other than Micro Enterprises and Small Enterprises	227.60	1.52	-	-	229.12	70.96	7.94	-	78.90
Total	290.34	9.59	(0.14)	-	299.79	101.41	14.78	-	116.19
Note 27 : Lease Liabilities (Current)									
Lease Liabilities	23.25	0.06	-	-	23.31	8.81	0.10	-	8.91
Total	23.25	0.06	-	-	23.31	8.81	0.10	-	8.91
Note 28 : Other Financial Liabilities (Current)									
Interest Payable	2.30	1.79	-	-	4.09	0.06	2.13	-	2.19
Expenses Payable	37.90	6.98	-	-	44.88	23.87	1.27	-	25.14
Ex Gratia	2.41	-	-	-	2.41	1.34	-	-	1.34
Payable to employees	15.44	-	-	-	15.44	12.65	-	-	12.65
Capital Creditor	0.91	0.62	-	-	1.53	0.41	2.76	-	3.17
Payable to group company	-	-	-	253.54	253.54	532.92	-	-	786.46
Total	58.96	9.38	-	253.54	321.88	571.25	6.16	-	830.95
Note No : 29 Provisions (Current)									
Gratuity	1.72	-	-	-	1.72	1.59	-	-	1.59
Total	1.72	-	-	-	1.72	1.59	-	-	1.59
Note 30 : Tax Liabilities (Current)									
Provision for income tax	110.17	27.05	-	-	137.22	77.13	23.97	-	101.10
Less: Advance income tax (including TDS & TCS)	(95.53)	(19.63)	-	-	(115.16)	(63.58)	(27.06)	-	(90.64)
Total	14.64	7.42	-	-	22.06	13.55	(3.09)	-	10.46
Note 31 : Other Liabilities (Current)									
Advance from customers	9.28	0.01	-	-	9.29	2.06	13.55	-	15.61
Statutory dues	22.17	5.44	-	-	27.61	6.06	4.32	-	10.38
Deferred Revenue - Capital Interest Subvention	-	4.06	-	-	4.06	-	4.93	-	4.93
Deferred Revenue - Capital Investment Incentive	-	40.18	-	-	40.18	-	41.67	-	41.67
Total	31.45	49.68	-	-	81.13	8.12	64.47	-	72.59



Bharat Pet Limited

CIN - U25209DL1998PLC091888

Notes to Unaudited Proforma Consolidated Financial Statements

(All amounts in INR million, unless otherwise stated)

Particulars	For the period ended September 30, 2025					For the year ended March 31, 2025						
	A	B	C	D	F=A+B+E	A	B	C	D	F=A+B+E		
	Restated Statement of Profit and Loss of Bharat Pet Limited for the period ended September 30, 2025	Special Purpose consolidated Statement of Profit & Loss of BPL Lifescience Private Limited for the period ended September 30, 2025	Intra Group Eliminations	Acquisition Adjustments	Total Pro-Forma Adjustments	Proforma Consolidated Statement of Profit and Loss of Bharat Pet Limited	Restated Statement of Profit and Loss of Bharat Pet Limited for the year ended March 31, 2025	Special Purpose consolidated Statement of Profit and Loss of Lifescience Private Limited for the year ended March 31, 2025	Intra Group Eliminations	Acquisition Adjustments	Total Pro-Forma Adjustments	Proforma Consolidated Statement of Profit and Loss of Bharat Pet Limited
Note 32: Revenue from Operations												
(a) Sale of products	2,261.99	498.45	(17.73)	-	(17.73)	2,742.71	3,324.55	817.12	(28.32)	-	(28.32)	4,113.35
(b) Other operating revenue	6.14	0.14	-	-	-	6.28	4.07	0.79	-	-	-	4.86
Total	2,268.13	498.59	(17.73)	-	(17.73)	2,748.99	3,328.62	817.91	(28.32)	-	(28.32)	4,118.21
Note 33: Other Income												
Interest Income	0.47	0.61	-	-	-	1.08	2.64	1.70	-	-	-	4.34
Foreign exchange fluctuation	-	-	-	-	-	-	-	0.21	-	-	-	0.21
Profit on sale of property, plant and equipment	1.76	0.01	-	-	-	1.77	3.19	-	-	-	-	3.19
Fair valuation gain on investments carried at FVTPL (net)	-	-	-	-	-	-	0.29	-	-	-	-	0.29
Profit on sale of investments	0.32	-	-	-	-	0.32	5.51	-	-	-	-	5.51
Interest Income on Security deposit	0.41	-	-	-	-	0.41	0.31	-	-	-	-	0.31
Miscellaneous Income	-	-	-	-	-	-	0.48	-	-	-	-	0.48
Capital Investment Incentive	-	1.49	-	-	-	1.49	-	2.98	-	-	-	2.98
Capital Interest Subvention	-	2.69	-	-	-	2.69	-	6.90	-	-	-	6.90
GST Refund	-	89.74	-	-	-	89.74	-	135.49	-	-	-	135.49
Total	2.96	94.54	-	-	-	97.50	12.42	147.28	-	-	-	159.70
Note 34: Cost of material consumed												
Raw material												
Opening	286.04	65.00	-	-	-	351.04	128.45	20.71	-	-	-	149.16
Purchase	1,076.19	215.19	(17.56)	-	(17.56)	1,273.82	2,125.54	557.80	(27.83)	-	(27.83)	2,655.51
Closing	137.79	24.48	-	-	-	162.27	286.04	65.00	-	-	-	351.04
Total	1,224.44	255.71	(17.56)	-	(17.56)	1,462.59	1,967.95	513.51	(27.83)	-	(27.83)	2,453.63



Vehicle running & maintenance	1.23	0.17	-	-	-	1.40	0.83	-	-	0.32	-	1.15
Freight & forwarding charges	59.66	9.31	-	-	-	68.97	77.94	-	-	14.09	-	92.03
Business promotion expense	1.55	-	-	-	-	1.55	2.87	-	-	-	-	2.87
Festival expense	-	-	-	-	-	-	2.59	-	-	-	-	2.59
Rebate & Discount	1.05	-	-	-	-	1.05	2.63	-	-	-	-	2.63
CSR expense	5.10	-	-	-	-	5.10	9.55	-	-	-	-	9.55
Security expense	2.33	0.82	-	-	-	3.15	2.85	-	-	1.63	-	4.48
Insurance expenses	2.41	1.19	-	-	-	3.60	2.64	-	-	1.74	-	4.38
Bad debt written off	-	-	-	-	-	-	0.24	-	-	-	-	0.24
Donation expenses	0.13	-	-	-	-	0.13	0.60	-	-	-	-	0.60
Capital work in Progress written off	-	-	-	-	-	-	1.18	-	-	-	-	1.18
Foreign Exchange Fluctuation	1.45	-	-	-	-	1.45	0.25	-	-	-	-	1.18
Miscellaneous expenses	0.48	0.85	-	-	-	1.33	3.35	-	-	-	-	0.25
Provision for credit impaired	1.32	0.01	-	-	-	1.33	0.50	-	-	5.39	-	8.74
Total	371.93	58.93	(0.03)	(0.03)	(0.03)	430.83	591.18	100.35	(0.35)	(0.35)	0.50	691.18
Note-40:Tax expenses												
Current Tax	110.17	27.05	-	-	-	137.22	136.30	23.97	-	-	-	160.27
Deferred Tax	(1.49)	(3.72)	-	-	-	(5.21)	(5.63)	16.52	-	-	-	10.89
Total	108.68	23.33	0.00	0.00	0.00	132.01	130.67	40.49	0.00	0.00	0.00	171.16
Note-41:Other Comprehensive Income												
Items that will not be reclassified to profit and Loss												
(i) Remeasurement of net defined benefit obligation	0.90	-	-	-	-	0.90	0.36	-	-	-	-	0.36
(ii) Income Tax related to above item	(0.23)	-	-	-	-	(0.23)	(0.09)	-	-	-	-	(0.09)
Total	0.67	0.00	0.00	0.00	0.00	0.67	0.27	0.00	0.00	0.00	0.00	0.27



Bharat Pet Limited
 CIN : U25209DL1998PLC091888
 Notes to Unaudited Proforma Consolidated Financial Statements
 (All amounts in INR million, unless otherwise stated)

Note:42: Contingent Liabilities and Commitments (to the extent not provided for)

Particulars	As at September 30, 2025			As at March 31, 2025				
	Bharat Pet Limited	BPL Life science Private Limited	Proforma Adjustment	Total	Bharat Pet Limited	BPL Life science Private Limited	Proforma Adjustment	Total
-Other*	-	74.17	-	74.17	-	74.17	-	74.17

* The company has imported machines having assessable value of Rs. 267.41 million during FY 2023-24 under the MOOWR scheme 2019 without payment of custom duty and IGST valuing Rs. 74.17 million. Under the scheme such duty was deferred till disposal of said machineries if disposed off in India and if such machineries are exported then such duty would be exempted.

Note 43: Related Party Disclosure (As required by Ind AS-24)

(A) List of related parties

(i) Key Management Personnel

Name	Designation
Vinod Kumar	Director (Resigned w.e.f. 18.06.2025)
Deepak Gupta	Whole-time Director and Chief Financial Officer
Ankur Gupta	Managing Director
Rahul Gupta	Whole-time Director
Subhash Chander Gupta	Director (ceased to be director w.e.f. 24.11.2024)
Sumit Bhatia	Whole-time Director (appointed w.e.f. 30.09.2025)
Surjit Singh	Company Secretary and Compliance Officer
Akash Gupta	Independent Director (appointed w.e.f. 14.08.2025)
Urvi Ka Aggarwal	Independent Director (appointed w.e.f. 14.08.2025)
Parveen Jain	Independent Director (appointed w.e.f. 14.08.2025)
Gaurav Kakkar	Independent Director (appointed w.e.f. 14.08.2025)

(ii) Relative of Key Management Personnel

- Meena Gupta
- Mitali Gupta
- Santosh Devi Gupta
- Sonu Gupta
- Suniti Gupta
- Ruchi Gupta
- Renu Gupta
- Anshika Gupta

(iii) Enterprises over which key management personnel of the reporting entity & their relative exercise significant influence with whom transaction have taken place during the year

- Bharat Pet Products Private Limited
- Reward Business Consolidation
- Modern Packaging Concept
- Bharat Products Limited
- Alka Laboratories Private Limited
- Bharat Plasto Tech
- Reward Business Portfolio Private Limited
- Deepak Gupta & Sons (HUF)/Karta - Deepak Gupta
- Ankur Gupta (HUF)/Karta - Ankur Gupta
- Subhash Gupta & Sons (HUF)/Karta-Ankur Gupta
- Gridlynk Solar LLP



Bharat Pet Limited
 CIN : U25209DL1998PLC091888
 Notes to Unaudited Proforma Consolidated Financial Statements
 (All amounts in INR million, unless otherwise stated)

*The transactions for the year ended 31st March 2025 have been eliminated except for the sale and purchase of property, plant and equipment.
 During the period under consideration, as part of an internal reorganisation under common control, 85% of equity share capital BPL Lifescience Private Limited has been acquired by Bharat Pet Limited.

The transaction has been accounted for as a business combination under common control in accordance with Appendix C to Ind AS 103 – Business Combinations, which requires assets and liabilities to be recognised at their existing carrying amounts without recognising any goodwill or gain.

In line with the principles of Appendix C to Ind AS 103, the financial statements reflect the transfer at historical carrying values, as the transaction represents a reorganisation of entities under common control and does not result in any change in economic substance or creation of value at the reporting entity level.

Since the transfer has been effected at carrying amount and does not give rise to any unrealised gain or loss, no adjustment has been considered necessary in respect of the transfer in the merged financial statements. Accordingly, the carrying amount of Property, Plant and Equipment continues to reflect the historical book values, and no impact on profit or equity arises from the transaction.

(ii) Outstanding balances

(A) Credit Balances

Name of Related Party	Nature of transaction	As at September 30, 2025			As at March 31, 2025			Total
		Bharat Pet Limited	BPL Life science Private Limited	Proforma Adjustment	Bharat Pet Limited	BPL Life science Private Limited	Proforma Adjustment	
Deepak Gupta	Director Remuneration	1.01	29.58	-	1.01	1.22	-	1.22
Rahul Gupta	Director Remuneration	0.48	-	-	49.66	4.42	-	50.22
Stuti Gupta	Borrowings	45.46	-	-	0.48	0.61	-	0.61
	Salary	-	9.34	-	88.00	42.23	-	98.23
Ankur Gupta	Borrowings	63.00	-	-	9.34	5.15	-	5.15
	Expense Payable	6.65	-	-	63.00	-	-	-
Meena Gupta	Director Remuneration	0.50	-	-	11.78	12.43	-	8.05
Mitali Gupta	Borrowings	-	-	-	0.01	-	-	-
Ankur Gupta (HUF)Karta - Ankur Gupta	Borrowings	-	68.82	-	0.50	-	-	20.48
Deepak Gupta & Sons (HUF) Karta- Deepak Gupta	Borrowings	-	59.61	-	68.82	38.37	-	83.84
		-	1.40	-	59.61	34.29	-	122.21
		-	-	-	1.40	-	-	61.00
		-	3.71	-	3.71	-	-	-



Bharat Pet Limited
CIN : U25209DL1998PLC091888
Notes to Unaudited Proforma Consolidated Financial Statements
 (All amounts in INR million, unless otherwise stated)

	100.55	59.89	26.44	86.33
Borrowings	-	-	-	-
Salary	76.42	1.04	94.08	95.12
Salary	0.30	0.42	-	0.42
Borrowings	-	-	-	-
Borrowings	7.44	7.44	-	0.42
Director Remuneration	19.84	-	2.93	2.93
Expense Payable	-	0.07	20.22	20.22
Expense Payable	0.01	-	-	0.07
Expense Payable	0.01	-	-	-
Trade Payable	-	-	-	-
Payable against slump purchase	59.47	-	-	-
Trade Payable	-	532.95	-	-
	0.14	-	-	532.95

(B) Debit Balances

Name of Related Party	Nature of transaction	As at September 30, 2025		As at March 31, 2025	
		Bharat Pet Limited	BPL Life science Private Limited	Bharat Pet Limited	BPL Life science Private Limited
Alka Laboratories Private Limited	Trade Receivables	0.67	-	-	-
	Rental Security	0.60	-	0.67	-
Bharat Products Limited	Trade Receivables	-	4.20	-	-
Bharat Venture Co (Proprietor - Meena Gupta)	Trade Receivables	0.20	-	35.21	-
BPL Lifescience Private Limited*	Trade Receivables	0.14	-	0.20	29.19
Deepak Gupta	Trade Receivables	0.88	-	-	-
	Rental Security	4.80	-	-	-
Rahul Gupta	Imprest Account	0.61	-	4.80	-
Modern Packaging Concept	Trade Receivables	0.95	-	-	-
Ankur Gupta	Advance to supplier	-	-	0.95	-
Meena Gupta	Rental Security	1.20	-	6.00	-
Lancer Packer Private Limited	Trade Receivables	4.80	-	1.20	-
		-	57.68	4.80	-
		-	-	57.68	-
		-	-	-	4.80
		-	-	-	4.80

Note 44

During the FY 2024-25, the Company (Bharat Pet Limited) has, for the purpose of preparation of its financial statements in accordance with Indian Accounting Standards (Ind AS), reassessed the method of computing depreciation on its property, plant and equipment. Previously, the Company was charging depreciation on a fixed rate basis under the Written Down Value (WDV) method. Upon first time preparation of its financials as per INDAS during the FY 2024-25, the Company has revised its approach and now computes depreciation using the Written Down Value (WDV) method based on the useful lives of the assets, as prescribed under Schedule II of the Companies Act, 2013 and based on management's technical assessment, where applicable. This change represents a change in accounting estimate in accordance with Ind AS 8 - Accounting Policies, Changes in Accounting Estimates and Errors. Accordingly, the effect of the change has been accounted for prospectively from the April 1, 2024. The impact of the aforesaid change on depreciation expense for the current period is ₹ 1.69 million from 97.33 million (IGAAP financials) to 99.02 million (INDAS financials). It is not practicable to estimate the effect of the change for future periods. During the period ended September 30, 2025, the Company (BPL Lifescience Private Limited) has, for the purpose of preparation of its financial statements in accordance with Indian Accounting Standards (Ind AS), reassessed the method of computing depreciation on its property, plant and equipment.

Previously, the Company was charging depreciation on a fixed rate basis under the Written Down Value (WDV) method. Upon first time preparation of its financials as per INDAS during the FY 2025-26, the Company has revised its approach and now computes depreciation using the Written Down Value (WDV) method based on the useful lives of the assets, as prescribed under Schedule II of the Companies Act, 2013 and based on management's technical assessment, where applicable. During the FY 2024-25 the company received a capital subsidy amounting to Rs. 50 million which was reduced from the gross block of assets in the IGAAP financials. However, while preparing the first time INDAS financials the said capital subsidy has been added back to the gross block of assets and has been shown at its present value in the INDAS financials. This change represents a change in accounting estimate in accordance with Ind AS 8 - Accounting Policies, Changes in Accounting Estimates and Errors. Accordingly, the effect of the change has been accounted for prospectively from April 1, 2025. The impact of the aforesaid change on depreciation expense for the current period is ₹ 5.17 million (IGAAP financials) to 41.89 million (INDAS financials). It is not practicable to estimate the effect of the change for future periods.

